2 INOVIQ Limited CEO’s Report We are advancing EXO-OC™ toward initial commercialisation as a Laboratory Developed Test (LDT) in the United States. OVERVIEW While development of our EXO-OC™ ovarian cancer test experienced an unexpected setback due to sample quality issues associated with commercially sourced biobank samples, the year also reinforced the strength of our technology platform, the quality of our science and the significant opportunity ahead. As we enter FY27, we are sharply focused on delivering a validation study that meets clinical and commercial partner requirements and progressing EXO-OC™ toward initial commercialisation in the United States through a CLIA-certified laboratory. We believe earlier detection of ovarian cancer has the potential to significantly improve outcomes for women and create substantial value for shareholders. EXOSOME TECHNOLOGY PLATFORM INOVIQ is building a differentiated biotechnology company around a powerful and highly versatile exosome technology platform. Our proprietary technologies already generate early revenue through commercial research tools and underpin a growing pipeline of highervalue diagnostics and therapeutics. By leveraging our exosome technology platform across multiple products and applications, we aim to create a scalable business with multiple opportunities for value creation. We are progressing from research tools to diagnostics and therapeutics, targeting larger global markets with greater clinical impact and commercial potential. This strategy is designed to deliver long-term growth while positioning INOVIQ at the forefront of the rapidly expanding exosome field. EXOSOME DIAGNOSTIC ADVANCING TOWARD LDT COMMERCIALISATION Our EXO-OC™ ovarian cancer test is being developed to address a critical unmet need in women’s health – the early detection of ovarian cancer. Encouraging clinical validation data generated to date continues to support the potential of EXO-OC™ as a highly accurate blood test for detecting ovarian cancer at an earlier and more treatable stage. Supported by our proprietary EXO-NET® technology, strategic collaborations and a staged commercialisation pathway, we are advancing EXOOC™ toward initial commercialisation as a Laboratory Developed Test (LDT) in the United States. This approach is intended to accelerate patient access, generate early revenue and establish a foundation for broader global adoption as an In Vitro Diagnostic (IVD) to expand market reach, support reimbursement and drive future growth. EXOSOME THERAPEUTICS PROGRESSING TOWARD FIRST-IN-HUMAN (FIH) STUDIES INOVIQ is also pioneering next-generation exosome therapeutics engineered to target and destroy solid tumours. Our CAR-exosome program has now demonstrated compelling proof-of-concept data across multiple cancer models, supporting its potential as a novel off-the-shelf alternative to traditional cell therapies. With encouraging preclinical efficacy and safety data generated across breast, lung and ovarian cancer models, we are continuing to advance the program toward manufacturing readiness and ultimately firstin-human studies. BUILDING A STRONGER COMPANY Beyond our development programs, FY26 was also a year of strengthening the foundations of INOVIQ. We raised $10.2 million to support our strategic priorities, expanded our leadership team with the appointment of Peter Gunzburg as Chairman and Dr Rebecca Lim as Chief Scientific Officer, and continued to grow the global reach of our EXO-NET® business through our partnership with Promega. These initiatives have enhanced our capability to execute, innovate and pursue commercial opportunities across our portfolio.
RkJQdWJsaXNoZXIy MjE2NDg3